VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Drive BiTAC Platform Advancement

VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.

Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development. The appointment comes as VERAXA seeks to build on its scientific foundation, which includes breakthroughs made at the European Molecular Biology Laboratory (EMBL).

The company’s BiTAC platform is designed to develop bispecific T cell engagers and other innovative antibody formats, including bispecific ADCs, for the treatment of solid tumors. By leveraging quality-by-design principles, VERAXA aims to rapidly advance its pipeline into clinical development. The full press release is available at https://nnw.fm/cR1RS.

This announcement is significant as it underscores VERAXA's commitment to strengthening its leadership team with deep expertise in immuno-oncology. Erkel's background in T-cell engagers at MorphoSys aligns with VERAXA's focus on bispecific antibodies, potentially accelerating the timeline for clinical trials. Investors and industry observers will be watching for updates on pipeline progression, particularly as the company aims to transition from preclinical to clinical stages.

VERAXA's forward-looking statements highlight risks and uncertainties inherent in drug development, including those detailed in its SEC filings. The company does not undertake to update forward-looking statements unless required by law. For the latest news and updates, visit the company’s newsroom at https://ibn.fm/VRXA.

The appointment of Dr. Erkel signals a strategic emphasis on advancing the BiTAC platform, which could position VERAXA as a key player in the bispecific antibody space. With his experience in leading multidisciplinary programs, Erkel is expected to drive the pipeline toward key value-creating milestones, including IND filings and early clinical data. The move also reflects the company's broader strategy to leverage its proprietary technologies to address unmet needs in solid tumor oncology.

As VERAXA continues to build its executive team, the focus remains on translating its scientific innovations into viable therapies. The company's foundation at EMBL and its registered BiTAC trademark underscore its commitment to rigorous science and differentiation in a competitive landscape. The upcoming transition period will be critical as Erkel assumes leadership and sets the strategic direction for research and development.